Avacta Lifts Dosing Cap and Sets Path to Efficacy Trials for Faridoxorubicin

Avacta Group plc ( (GB:AVCT) ) has issued an announcement.

Avacta Therapeutics has reported two significant clinical milestones for its lead pre|CISION®-based drug candidate faridoxorubicin (AVA6000), including the removal of a historic maximum dosing limit tied to free doxorubicin exposure after Phase 1 data showed highly favourable cardiac safety, even at nearly four times the conventional dose and higher cumulative exposure with no severe cardiac toxicity observed. The company has also clarified the path to dose selection for future efficacy trials by enrolling final Phase 1b cohorts to compare two dose levels and determine the optimal biologic dose, developments that reinforce regulatory confidence in the safety of the pre|CISION® platform and are expected to smooth the transition into later-stage studies while supporting Avacta’s broader strategy to advance its tumor-activated oncology pipeline.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £49.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Spark’s Take on GB:AVCT Stock

According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.

Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on GB:AVCT stock, click here.

More about Avacta Group plc

Avacta Therapeutics, a subsidiary of Avacta Group plc, is a clinical-stage biopharmaceutical and life sciences company focused on oncology. It is developing its proprietary pre|CISION® tumor-activated drug delivery platform, which uses a fibroblast activation protein (FAP)-targeted peptide system to concentrate potent cancer therapies in the tumor microenvironment while limiting exposure to healthy tissues, and its pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates designed to improve tolerability and dosing of anticancer treatments.

Average Trading Volume: 2,534,461

Technical Sentiment Signal: Sell

Current Market Cap: £225.3M

For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.